DR. LISSA PIPELEERS (Orcid ID : 0000-0003-4808-8016)

DR. STEVEN VAN LAECKE (Orcid ID : 0000-0001-7628-8491)

5-YEAR OUTCOMES OF THE PROSPECTIVE AND RANDOMIZED CISTCERT STUDY COMPARING STEROID WITHDRAWAL TO REPLACEMENT OF CYCLOSPORINE WITH EVEROLIMUS IN DE NOVO KIDNEY TRANSPLANT PATIENTS

Lissa Pipeleers, MD, Department of Nephrology, Universitair Ziekenhuis Brussel, Brussels, Belgium

Daniel Abramowicz, MD PhD, Department of Nephrology, Centre Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium; Department of Nephrology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium

Nilufer Broeders, MD PhD, Department of Nephrology, Centre Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium

Alain Lemoine, MD PhD, Department of Nephrology, Centre Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium

Patrick Peeters, MD, Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

Steven Van Laecke, MD PhD, Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

Laurent E Weekers, MD PhD, Department of Nephrology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, Liège, Belgium

Jacques Sennesael, MD, Department of Nephrology, Universitair Ziekenhuis Brussel, Brussels, Belgium

Karl M Wissing MD, PhD, Department of Nephrology, Centre Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium; Department of Nephrology, Universitair Ziekenhuis Brussel, Brussels, Belgium

Caroline Geers, MD, Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium

Jean-Louis Bosmans, MD PhD, Department of Nephrology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium

Authorship

- Lissa Pipeleers performed the analysis of the data and the writing of the paper
- Daniel Abramowicz participated in the performance of the study and the writing of the paper
- Nilufer Broeders participated in the performance of the study
- Alain Lemoine participated in the performance of the study
- Patrick Peeters participated in the performance of the study
- Steven Van Laecke participated in the performance of the study and the writing of the paper
- Laurent E Weekers participated in the performance of the study
- Jacques Sennesael participated in the performance of the study and the writing of the paper
- Karl M Wissing participated in the performance of the study, data analysis and writing of the paper
- Caroline Geers participated in the performance of the study

- Jean-Louis Bosmans, principal investigator, participated in study design, acquisition and analysis of data, the performance of the study, and the writing of the paper.

Corresponding information

Lissa Pipeleers

Universitair Ziekenhuis Brussel

Department of Nephrology

Laarbeeklaan 101

B-1090 Brussels

Belgium

email address: lissa.pipeleers@uzbrussel.be

Running Title

Discontinuation of steroids versus CNI's: a RCT with long-term follow-up

Key words

Kidney transplantation

Immunosuppression

Cyclosporine

CNI

Everolimus

mTORi

Conflict of interest statement

The authors have no conflict of interest to declare.

Abstract

Background: Withdrawal of either steroids or calcineurin inhibitors are two strategies to reduce treatment-related side effects and improve long-term outcomes of kidney transplantation. The Cistcert study compared the efficacy and safety of these two strategies.

Methods: In this multi-center, randomized controlled trial, 151 incident kidney transplant recipients received cyclosporine (CsA), mycophenolic acid (MPA) and steroids during three months, followed by either steroid withdrawal (CsA/MPA) or replacement of cyclosporine with everolimus (EVL) (EVL/MPA/steroids).

Results: Five-year patient (89% vs 86%; p=NS) and death-censored graft survival (95% vs 96%; p=NS) were comparable in the CsA/MPA and EVL/MPA/steroids arm respectively. [51]CrEDTA clearance was comparable in the intention-to-treat analysis, but in the on-treatment population, the EVL/MPA/steroids arm exhibited a superior [51]CrEDTA clearance at 1 and 5 years after transplantation (61.6 vs 52.4, p=0.05 and 59.1 vs 46.2mL/min/1.73 m^2, p=0.042). Numerically more and more severe rejections were observed in the EVL/MPA/steroids arm, which also experienced a higher incidence of post-transplant diabetes (26% versus 6%, p=0.0016) and infections. No significant differences were observed in cardiovascular outcomes and malignancy.

Conclusions: Both regimens provide an excellent long-term patient and graft survival. Regarding graft function, EVL/MPA/steroids is an attractive strategy for patients with good tolerability who remain free of rejection.

 (ClinicalTrials.gov number: NCT00903188; EudraCT Number 2007-005844-26)

Abbreviations

Anti-thymocyte globulin (ATG)

Biopsy proven acute rejection (BPAR,)

CNI versus STeroid CEssation in Renal Transplantation (CISTCERT)

Cytomegalovirus (CMV)

Calcineurin inhibitor (CNI)

Cyclosporine (CsA)

Donor-specific anti-HLA antibodies (DSA)

Everolimus (EVL)

Glomerular filtration rate (GFR)

Graft survival (GS)

Intima media thickness (IMT)

Intention-to-treat (ITT)

Left ventricular mass (LVM)

Major adverse cardiac event (MACE)

Mycophenolic acid (MPA)

Modified intention-to-treat (mITT)

mTOR inhibitors (mTORi)

On-treatment (OT)

Patient survival (PS)

Post-transplant diabetes mellitus (PTDM)

Randomized controlled trial (RCT)

Serious adverse event (SAE)

Introduction

Nephrotoxic, cardiovascular and metabolic adverse effects of immunosuppressive drugs are increasingly recognized to impair long-term outcomes of kidney transplantation. Calcineurin inhibitors (CNIs) cause nephrotoxicity, characterized by a functional decrease in renal blood flow and non-reversible histological lesions [1-3]. CNIs are associated with hypertension, hyperlipidemia and posttransplant diabetes (PTDM) [4]. Steroids cause dyslipidemia and hypertension in kidney transplant recipients [4-7] and by inducing insulin resistance increase the risk for PTDM, which is associated with a reduced patient and graft survival [4-6, 8-10].

One strategy to reduce the negative impact of immunosuppressants consists in steroid withdrawal in patients maintained on CNIs and mycophenolic acid (MPA) to avoid side effects of steroids and prevent PTDM [11],[12]. An alternative strategy replaces CNIs with mTOR inhibitors (mTORi) to avoid chronic nephrotoxicity and reduce the long-term risk of cancer [13]. This is based on findings in preclinical models showing everolimus-induced inhibition of renal interstitial fibrosis and tubular atrophy [14, 15]. Further support comes from reduced incidence of cardiac allograft vasculopathy in heart transplant patients treated with sirolimus and everolimus and from the lower incidence of post-transplant malignancies with mTORi [16, 17], [18-20]. Another potential advantage of mTORi is its anti-viral action against CMV and BK-polyomavirus infections [21].

Each strategy has been the subject of several trials and is currently used in clinical practice. However, they have not yet been evaluated in a comparative analysis of major clinical endpoints – i.e. long term renal function, rejection episodes, patient and graft survival. The randomized, controlled, multi-center CISTCERT study (CNI versus STeroid CEssation in Renal Transplantation) with 5 years follow-up was designed to address this question. In this trial, 151 patients were randomized, to convert at post-transplant month three to either steroid withdrawal or replacement of cyclosporine by everolimus. The primary endpoint was glomerular filtration rate at 1 year after transplantation.

Materials and methods

Study design and conduct

Cistcert is a 5-year, prospective, multi-center, open-label, randomized controlled trial (RCT), conducted at 5 Belgian kidney transplant centers during the period October 2008 (FirstPatientFirstVisit) to September 2016 (LastPatientLastVisit), in which patients were randomized to discontinue either steroids or replace cyclosporine with everolimus at 3 months after transplantation. The study intended to compare maintenance immunosuppression regimens without steroids or CNI in terms of graft function, graft survival, graft histology and surrogate markers for cardiovascular outcomes during the first five years after transplantation. The Cistcert trial was conducted in compliance with the 2000 Declaration of Helsinki, the declaration of Istanbul 2008 and with the principles of Good Clinical Practice. The study was approved by ethics committees in all participating centers (Institutional Review Board approval number OG 085; protocol number CRAD 001ABE06T). The trial was registered in both ClinicalTrials.gov (NCT00903188) and EudraCT (2007-005844-26) registries.

Study Population

Between October 2008 and September 2011, 155 adult recipients of a de novo renal allograft from a living or deceased donor were recruited. 151 patients were included in the study and randomly assigned at center level to one of the two treatment groups within 24 hours prior to transplantation. After providing written informed consent, patients were randomized by opening numerically consecutive sealed envelopes containing treatment allocation generated by a validated automated procedure. Main exclusion criteria were highly immunized recipients and cytopenia. An overview of exclusion criteria is provided in Supplementary Table 1. All patients had a complete 5-year follow-up, except those patients with any of following conditions: graft loss, death, withdrawal of consent, lost to follow-up.

Immunosuppression

During the first three months of the study, all patients received the same immunosuppressive regimen consisting in anti-IL2 receptor mAbs (Simulect®), enteric-coated MPA (Myfortic®), methylprednisolone and cyclosporine (CsA) (Neoral®) (Fig. 1). At transplantation, 76 patients were randomized to withdraw steroids at three months after transplantation while continuing on CsA and MPA, and 75 patients were randomized to replace CsA by EVL in combination with MPA and steroids (Fig. 1). Exclusion criteria for discontinuation of steroids or conversion from CsA to EVL included any episode of treated acute rejection, dialysis-dependency, as well as any other medical condition precluding discontinuation of steroids or conversion to EVL in the opinion of the investigators. Patients randomized to the CsA/MPA arm who did not discontinue steroids, and patients randomized to the EVL/MPA/steroids arm who were not converted to everolimus, remained in the study and were analyzed on intention-to-treat (ITT) basis. Their treatment was left at the discretion of the local investigator. Per protocol all patients who received at least one day of the allocated regimen were analyzed as a modified intention to treat (mITT) population. Patient and graft survival as well as measured and estimated GFR are also reported for the full ITT population of all included patients.

Treatment of acute rejection

Treatment of acute rejection consisted in an IV bolus of methylprednisolone (500 or 1000 mg) on three consecutive days. In case of steroid resistant acute rejection or vascular rejection, treatment with antithymocyte globulin (ATG) was given. Plasmapheresis plus intravenous immunoglobulin therapy was administered for the treatment of antibody-mediated rejection, at the discretion of the local investigator.

Concomitant therapies

Pneumocystis jirovecii prophylaxis was administered for the first three months after transplantation. CMV-prophylaxis or pre-emptive treatment was provided during the

first three months according to center practice. The use of antihypertensive and/or lipid-lowering drugs was left at the discretion of the local investigator.

Renal biopsies

Renal biopsies at baseline and one year after transplantation were mandatory per study protocol. An additional protocol biopsy could be performed at 3 months at the discretion of the local investigator. Indication biopsies had to be performed in all suspected episodes of acute rejection. All graft biopsies were initially evaluated by a local pathologist, and then reviewed centrally by a dedicated nephropathologist (C.G.), who was blinded to the randomization and to the initial diagnosis at the local center.

Study endpoints

The primary endpoint of the CISTCERT study was the glomerular filtration rate (GFR) measured by ^{51}CrEDTA clearance at one year after transplantation. Graft function at one year after transplantation correlates with long-term graft function, long-term graft survival and patient survival [22-25]. A difference of 10mL/min/1.73m2 in GFR is considered a clinically significant as well as a realistic target based on outcomes of other RCT [26-28].

Secondary endpoints were GFR estimated by the MDRD formula, patient and graft survival, rejection episodes, diabetes, malignancies, infections, cardiovascular endpoints, and proteinuria. A detailed description of the secondary endpoints is provided in Supplementary Table 2.

Statistical analysis

The sample size calculation for the primary endpoint predicted that a total population of 128 patients (64 patients per group) would provide an 80% power and two-sided significance level of 5% to detect a difference in GFR of 10mL/minute. Taking into account a dropout at the time of the conversion at 3 months of 15% of the initially included patients, 152 patients (76 patients per study group) needed to be included in the study. Analysis was performed on an intention-to-treat basis. The intention-to-

treat (ITT) population was defined as the subset of all subjects who have been randomized and not censored at the moment of analysis. A modified intention-to-treat (mITT) population was defined as the set of all subjects, who have been randomized and treated with the allocated regimen for at least one day. All statistical analyses were performed in Medcalc version 18.11. Comparison between the two treatment arms was performed by means of an independent samples T test. In case of unequal distribution or low number of participants, statistical analysis was performed by the Mann-Whitney test. Patient and graft survival were estimated by a Kaplan-Meyer survival analysis. Safety data were analyzed descriptively, and were compared statistically by Chi-square and Fisher exact test for comparison of 2 proportions. The protein/creatinine in urine was categorized ($\leq$ 0.5, 0.5-1.0, $\geq$ 1.0) and comparison between both groups was performed by Chi-square and Fisher exact test for comparison of 2 proportions. All statistical tests were interpreted at the two-sided 5% significance level.

Results

Overview of patients and immunosuppressive regimens

At baseline, donor and recipient characteristics were well balanced between treatment arms except for a higher dialysis vintage, a trend for higher recipient age and less NHBD in the CsA/MPA arm compared to the EVL/MPA/steroids arm (Table 1). 70 of the 76 patients who were allocated to the CsA/MPA and 54 of the 75 patients allocated to the EVL/MPA/steroids arm have been treated at least one day with the allocated treatment. 25 patients in the CsA/MPA arm (36%) and 20 patients in the EVL/MPA/steroids arm (37%) remained on the assigned treatment during the entire 5-year follow-up (Fig. 2). An overview of the reasons for discontinuation of study medication and main types of adverse events leading to discontinuation is provided in Supplementary Tables 3 and 4. 53 patients in the CsA/MPA arm (76%) and 43 patients in the EVL/MPA/steroids arm (80%) completed the five-year follow-up.

In both groups, blood concentrations of cyclosporine and everolimus were within the target limits of the study before and after randomization. Mean MPA doses were lower than intended in the protocol. MPA doses were significantly lower in the EVL arm throughout the entire follow-up (Table 2).

Graft function

As expected, the ^{51}CrEDTA clearance was similar in both treatment arms at 3 months. There was no significant difference in ^{51}CrEDTA clearance in the mITT as well as in the ITT analysis neither at 1y (primary endpoint) nor at 5y. We observed a significant difference of 9.2 ml/min/1.73m^2 in the on-treatment (OT) analysis in favor of the group EVL/MPA/Steroids at 1 year and of 12.9mL/min/1.73 m^2 at 5 years (Table 3). MDRD clearance was comparable in both groups in both the ITT and the mITT analysis (Table 3).

Patient and graft survival

Survival outcomes were comparable in both groups, both in the mITT analysis (Fig. 3) and in the ITT analysis (Supplementary Table 5). In the CsA/MPA arm and the EVL/MPA/steroids arm respectively, 5-years death-censored graft survival was 95% and 96%, overall graft survival 85% and 83%,(Fig. 3) and patient survival 89% and 86%.

Acute rejection

During the first three months after transplantation, 8 acute rejection episodes had occurred in 151 patients. After discontinuation of steroids or conversion to everolimus, respectively 5 biopsy-proven acute cellular rejections (BPAR) > borderline were diagnosed in 70 patients in the CsA/MPA arm and 8 BPAR > borderline in 54 patients in the EVL /MPA/steroids arm (p = 0.238). The number of borderline rejections was 4/70 in the CsA/MPA-group compared to 1/54 in the EVL/MPA/steroids arm (p=0.27). Two antibody-mediated rejections occurred in the CsA/MPA group and one in the EVL/MPA/steroids group. Overall, the incidence of severe acute rejections (≥ Banff 1B or ABMR) was 4/70 patients and 5/54 patients respectively (Table 4, p = 0.5).

Proteinuria

Both mITT (Supplementary Table 6) and OT analysis (data not shown) showed no significant differences in proteinuria between both groups, although there was a numerically higher proportion of patients with Urine Prot/Creat ≥ 1.0 g/g creatinine in the EVL/MPA/steroids group (16.6%) compared to the CsA/MPA group (8.6%). We also observed a trend to a higher proportion of patients treated with ACEI/ARB in the EVL/MPA/steroids group (70% vs 53%; p=0.06). In 3/54 patients, proteinuria was reported as a reason for discontinuation of everolimus (Supplementary Table 4).

Cardiovascular endpoints

The incidence of major adverse cardiac events (MACEs) was 7/70 (10%) in the CsA/MPA group compared to 4/54 (7.4%) in the EVL/MPA/steroid group during the 5-year follow-up (p = 0.61). There were no significant differences between both groups in the mITT analysis for intima media thickness or left ventricular mass at baseline and at 5 years (results not shown). Blood pressure was well controlled during the 5-year follow-up without significant differences between both treatment arms. However, a trend for a lower blood pressure in the everolimus group could be observed at year 4 and 5 (Supplementary Table 7).

Post-transplant diabetes mellitus

The incidence of PTDM during the 5 years follow-up was significantly lower in the CsA/MPA arm than in the EVL/MPA/steroid arm (4/70 (6%) vs 14/54 (26%), p = 0.0016).

Infections and malignancies

The incidence of infections as well as the incidence of serious adverse events (SAEs) associated to an infection was significantly higher in the everolimus treatment arm (p = 0.04 and P = 0.015 respectively). More urinary tract (p = 0.0005) and less pulmonary (p = 0.025) infections were observed in the CsA/MPA arm than in the EVL/MPA/steroids arm (Table 5). There was a trend towards a higher incidence of malignancy (solid organ and skin tumors) in the EV/MPA/steroids arm compared to the CsA/MPA arm during the 5-year follow-up in the mITT analysis (p = 0.06). The majority of skin tumors were basocellular and squamous cell carcinomata and were diagnosed during the last 2 years of follow-up. The proportion of patients developing at least one malignancy was comparable in both groups (p = 0.1) (Table 5).

Kidney biopsies

At baseline, the proportion of normal implantation biopsies was comparable between both groups: 66% in the CsA/MPA arm and 63% in the EVL/MPA/steroids arm (Supplementary Table 8). At 1 year protocol biopsies were available in 24 patients of the CsA/MPA group and 18 patients of the EVL/MPA/steroids group with no significant difference in chronic histological damage between the two groups (Supplementary Table 9).

Discussion

Primary endpoint

Notwithstanding some rare exceptions [29], the majority of previous clinical trials [13, 27, 30-33], as well as a meta-analysis [34] have reported improvements in GFR after replacement of a CNI by an mTORi. The beneficial effect of the conversion however was often limited to the on-treatment population in several studies [31-33, 35].

In the Cistcert trial, the primary endpoint was not met, since the 6 ml/min/1.73 m^2 improvement in ^{51}CrEDTA clearance of the EVL/MPA/steroids group at 1 year in the mITT analysis did not reach statistical significance. However, this lack of effect probably reflected the fact that a large proportion of patients in the ITT population in this arm received calcineurin inhibitor-based therapy. Analysis of the on-treatment data of patients who remained on EVL/MPA/steroids documented an improvement of 9 ml/min in ^{51}CrEDTA clearance that was statistically significant at one year and persisted during the 5-year follow up. Conversion towards EVL/MPA/steroids might therefore be a good strategy for a subset of patients, who experience good tolerability and remain free of rejection under an EVL/MPA/steroid treatment. This subset of patients was relatively small in our study (37% after 5 years) because the majority of patients had been re-converted towards another immunosuppressive regimen for a variety of reasons. Nevertheless, taking into account the excellent overall graft and patient survival observed in our trial, an attempt for conversion towards EVL/MPA/steroids might be justifiable in selected patients at low immunological risk

Patient and graft survival

Our study shows excellent and equivalent long-term patient (PS) and graft survival (GS) for both treatment arms (5-year PS of 89 and 86% and death-censored GS of 95% and 96% in the CSA/MPA and EVL/MPA/steroids arm respectively), compared to the recently published European 5-year death-censored kidney graft survival rate (84.4%) [36]. Our outcomes are similar to those of many other conversion trials [13, 30-32] and a meta-analysis [34]. To our best knowledge the Cistcert trial is the first

interventional trial in kidney transplantation with 5-year follow-up demonstrating the safety of steroid withdrawal in terms of graft survival in low-risk patients receiving CsA in combination with MPA.

Rejection

The incidence of acute rejection of the overall cohort during the first three months was low (8/151; 5.3%), confirming the excellent efficacy of basiliximab in combination with standard immunosuppressive therapy. A significant proportion of patients in both groups developed acute rejection after either steroid withdrawal or replacement of CsA with EVL. Steroid withdrawal in combination with tacrolimus is associated with a minimal increase in the risk of acute rejection [37, 38]. The present study confirms previous reports that steroid withdrawal in patients treated with cyclosporine is associated with a significant risk of acute rejection [39, 40]. The higher risk of acute rejection of mTORi-based immunosuppression as compared to standard triple therapy is well documented [13, 29, 31, 34, 41-45]. The current protocol directly compared mTORi-based immunosuppression to steroid avoidance in combination with cyclosporine. The number of rejection episodes was numerically higher in the EVL/MPA/steroids arm but the difference did not attain statistical significance. Although not powered to detect differences in acute rejection, the current study nevertheless allows to conclude that both strategies imply a relatively high risk of late and sometimes severe acute rejection in a population selected to be at low immunological risk.

Unfortunately, data on anti-HLA antibodies were not collected in the CISTCERT study, as well as in many other randomized controlled trials that were designed in the same period. However, retrospective data of conversion to CNI-free EVL-based regimens [46, 47] and limited data available from randomized controlled trials [13, 29, 45, 48], raise concerns about the development of de novo donor-specific anti-HLA antibodies (DSA) and antibody-mediated rejection. In the light of current knowledge about the detrimental effect of DSA, we would now consider pre-existing DSA as a contra-indication for participation to the Cistcert trial, and in case of occurrence of de novo

DSA, we would no longer consider it safe to convert to one of the proposed minimization strategies.

Diabetes

The incidence of PTDM was significantly lower in the steroid withdrawal group remaining on cyclosporine compared to the patients that were converted to everolimus and continued steroids. We attribute this difference mainly to the discontinuation of steroids, although a role of the known diabetogenic effect of mTORi (combined to low-dose steroids) cannot be excluded [44, 49].

Several studies have shown a benefit of early steroid withdrawal and steroid avoidance on the incidence of post-transplant diabetes [50, 51]. Our data are in line with those in two meta-analysis showing that both late steroid withdrawal and steroid avoidance in patients treated with CsA were associated with a 50% reduction in PTDM although at the price of a significant increase in acute rejection episodes [39, 52].

Infections

We observed a significantly higher incidence of infections in the group of patients converted to Everolimus. This observation is in contrast to other conversion trials [13, 29, 31, 33] and a meta-analysis [44]. While we observed more genito-urinary infections in the cyclosporine arm and more pulmonary infections in the everolimus arm, a finding that might have been confounded by pulmonary toxicity of everolimus. Importantly, the incidence of infections reported as SAEs was significantly higher in patients who converted from cyclosporine to everolimus. This was mainly due to a higher hospitalization rate for parenteral antibiotherapy. No difference was observed in the incidence of CMV-infections between both treatment arms. The strength of these data is however limited due to the absence of standardized diagnostic criteria for the diagnosis of CMV- infection in the study protocol. The reported incidence of BK-polyomavirus infections was equal in both treatment arms, but the numbers were very low.

Malignancy

We observed a numerically higher incidence of overall malignancies (skin and solid organ tumors) in patients converted from cyclosporine to everolimus compared to patients remaining on cyclosporine and MPA, although for both outcomes the difference did not reach statistical significance. Interpretation remains however difficult due to the small sample size and the relatively large number of patients who discontinued study treatment. In fact, most patients who developed a skin tumor in the everolimus arm had previously discontinued study treatment, and had been re-converted to a CNI.

Cardiovascular endpoints

We did not detect significant differences in cardiovascular endpoints between both treatment arms, but the trial was likely underpowered to detect differences in rare events such as MACEs. Our results confirm the reports by three other RCTs that have failed to demonstrate relevant effects on cardiovascular end points after conversion from CNI to an mTORi based CNI-free regimen [53-55].

Histology

In terms of development of allograft fibrosis, the conversion from a CNI towards an mTORi was beneficial in one previous RCT [27] but not in another [45] . We were unable to detect a lower incidence of chronic histological lesions in patients who were converted to everolimus as compared to patients remaining on cyclosporine without corticosteroids. We acknowledge that the low number of available protocol biopsies at 1 year limits a reliable comparison of the long-term histologic effects of both treatment arms.

Discontinuations and tolerability

By the end of the 5 years follow-up of our study, the proportion of patients who had discontinued study treatment was high, but comparable in both treatment arms (64% in the CsA/MPA arm and 63% in the EVL/MPA/steroids arm). Historically, high rates of discontinuations have been reported in many conversion trials [27, 29, 31-33, 35, 56] and occurred predominantly in the mTORi arm as a consequence of poor tolerance or adverse events [27, 29, 32, 56]. In our study, there was a trend for a higher number of discontinuations as a consequence of adverse events in the everolimus group, although this was not significant.

Strengths and limitations

In the EVL/MPA/steroids arm, the number of patients that had been initially randomized, but failed to be converted from CsA to EVL at three months after transplantation according to the study protocol, was higher than the 15% predicted. As a consequence, the study was slightly underpowered as to the primary efficacy endpoint. Primary and secondary outcomes were analyzed on a 'modified intention-to-treat' (mITT) population, defined as the subset of patients who had taken the allocated treatment for at least one day. This mITT population corresponds to the ITT-population of the Zeus study, in which the efficacy analysis was performed on all patients who were randomized at 4.5 months after transplantation and who received at least one dose of any immunosuppressive drug [35]. In our study, the mITT population included 70 patients in the CsA/MPA arm and 54 patients in the EVL/MPA/steroids arm. The unequal number of patients (70 and 54) in both treatment arms could reflect a selection bias. However, the results of mITT and ITT (defined as all randomized patients at the time of transplantation), were comparable for both the primary endpoint and the survival analysis (Table 3 and Supplementary Table 5). The sample size of our study might have been too small to discover statistically significant differences for secondary endpoints such as long-term graft function, incidence of rejection and malignancies. The frequent crossover between both treatment strategies, with re-introduction of a CNI in the EVL/MPA/steroids arm, and re-introduction of steroids in the CsA/MPA arm, represents an important limitation when outcome of these strategies is under evaluation. However, frequent

adaptation of medication according to signals of over- and under- immunosuppression and drug tolerance reflects current clinical practice where tailored immunosuppression and precision medicine are increasingly recommended [57-59].

Although our study shows that replacement of CsA with EVL results in significantly improved graft function up to 5 years in those patients tolerating EVL without treatment failure, it was not powered to identify predictors of treatment failure. However, the excellent graft and patient survival overall in the EVL/MMF/steroids arm suggests that conversion can be attempted in selected patients with acceptable risk.

Another limitation of our study is the lack of a CNI-based triple therapy control group. The present study was indeed designed to compare two interventions aiming at either improving metabolic side effects or renal function after renal transplantation. The important question whether each of these two interventions improves outcomes as compared to standard of care therapy had been previously investigated by several large-scale intervention trials [13, 39, 60].

To our knowledge, this is the first study in kidney transplantation that prospectively compares the long-term outcomes of steroid withdrawal to CNI-withdrawal. The 5-year follow-up, multicenter and randomized controlled design reinforces the validity and credibility of the results.

Conclusions

In the Cistcert trial, an advantage in graft function after conversion towards EVL/MPA/steroids could only be observed in a select group of patients, i.e. those who were able to remain on treatment. Patient and graft survival were excellent for both immunosuppressive strategies. A relatively high number of rejections occurred in both treatment arms, with numerically more and more severe rejections in the EVL/MPA/steroids arm. Dual therapy with CsA and MPA was associated with fewer serious infections as compared to the EVL/MPA/steroids regimen. Steroid cessation in the CsA/MPA arm was associated with a significantly lower incidence of PTDM. The Cistcert trial did not show a benefit of conversion to an mTORi in terms of malignancy, cardiovascular outcomes or graft fibrosis, but the trial was not powered to detect these differences. We conclude that the Cistcert trial provides evidence for the feasibility of conversion to any of the investigated immunosuppressive regimens based on the individual recipient's needs and risk profile. Regarding graft function, EVL/MPA/steroids is an attractive strategy for patients with good tolerability who remain free of rejection.

Part of this work was presented at:

1°. The Annual Meeting of the Belgian Transplantation Society 2017 Brussels

2°. The Annual ERA-EDTA Congress 2017 Barcelona

ACKNOWLEDGEMENTS

REFERENCES

1.   English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. *Transplantation*. 1987; **44**: 135.

2.   Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. *The New England journal of medicine*. 1984; **311**: 699.

3.   Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. *Transplantation*. 2004; **78**: 557.

4.   Wissing KM, Pipeleers L. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. *Transplantation reviews (Orlando, Fla)*. 2014; **28**: 37.

5.   Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. *Lancet (London, England)*. 2011; **378**: 1419.

6.   Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. *Clinical journal of the American Society of Nephrology : CJASN*. 2008; **3 Suppl 2**: S101.

7.   Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. *Transplant international : official journal of the European Society for Organ Transplantation*. 2011; **24**: 523.

8.   Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. *Kidney international*. 2006; **69**: 588.

9.   Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. *Clinical journal of the American Society of Nephrology : CJASN*. 2008; **3**: 814.

10. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2003; **3**: 178.

11. Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2008; **23**: 2033.

12. Pirsch JD, Henning AK, First MR, et al. New-Onset Diabetes After Transplantation: Results From a Double-Blind Early Corticosteroid Withdrawal Trial. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015; **15**: 1982.

13. Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015; **15**: 119.

14. Koch M, Mengel M, Poehnert D, Nashan B. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. *Transplantation*. 2007; **83**: 498.

15. Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. *Transplantation*. 2003; **76**: 508.

16. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *The New England journal of medicine*. 2003; **349**: 847.

17. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. *Circulation*. 2004; **110**: 2694.

18. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. *The oncologist.* 2010; **15**: 236.

19. Holdaas H, De Simone P, Zuckermann A. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. *Journal of transplantation.* 2016; **2016**: 4369574.

20. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet (London, England).* 2008; **372**: 449.

21. Fantus D, Rogers NM, Grahammer F, Huber TB, Thomson AW. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. *Nature reviews Nephrology.* 2016; **12**: 587.

22. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. *Kidney international.* 2002; **62**: 311.

23. Kasiske BL, Israni AK, Snyder JJ, Skeans MA. The relationship between kidney function and long-term graft survival after kidney transplant. *Am J Kidney Dis.* 2011; **57**: 466.

24. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. *Transplantation.* 2003; **75**: 1291.

25. Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. *Transplantation.* 2006; **81**: 202.

26. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. *Lancet (London, England).* 2011; **377**: 837.

27. Bemelman FJ, de Fijter JW, Kers J, et al. Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. *American journal of transplantation : official journal*

of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017; **17**: 1020.

28. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2005; **5**: 2496.

29. de Fijter JW, Holdaas H, Oyen O, et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2017; **17**: 1853.

30. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2009; **9**: 1115.

31. Mjornstedt L, Schwartz Sorensen S, von Zur Muhlen B, et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. *Transplant international : official journal of the European Society for Organ Transplantation.* 2015; **28**: 42.

32. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. *Transplantation.* 2009; **87**: 233.

33. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. *Kidney international.* 2011; **79**: 897.

34. Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized,

Controlled Trials. *Clinical journal of the American Society of Nephrology : CJASN*. 2017; **12**: 1321.

35.   Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2012; **12**: 1528.

36.   Coemans M, Susal C, Dohler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. *Kidney international*. 2018; **94**: 964.

37.   Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. *Transplantation*. 2006; **82**: 55.

38.   Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2005; **5**: 87.

39.   Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. *Transplantation*. 2010; **90**: 343.

40.   Torres A, Hernandez D, Moreso F, et al. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. *Kidney international reports*. 2018; **3**: 1304.

41.   Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2011; **11**: 1633.

42. Frei U, Daloze P, Vítko S, et al. Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. *Clinical transplantation*. 2010; **24**: 500.

43. Kumar J, Bridson JM, Sharma A, Halawa A. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel. *Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation*. 2017; **15**: 241.

44. Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2014; **14**: 2317.

45. Rostaing L, Hertig A, Albano L, et al. Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015; **15**: 1303.

46. Kamar N, Del Bello A, Congy-Jolivet N, et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. *Clinical transplantation*. 2013; **27**: 455.

47. Croze LE, Tetaz R, Roustit M, et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. *Transplant international : official journal of the European Society for Organ Transplantation*. 2014; **27**: 775.

48. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2012; **12**: 1192.

49. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. *Journal of the American Society of Nephrology : JASN*. 2008; **19**: 1411.

50. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. *Transplantation*. 2006; **81**: 832.

51. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. *Transplantation*. 2005; **79**: 807.

52. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2012; **27**: 825.

53. Holdaas H, de Fijter JW, Cruzado JM, et al. Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study. *Transplantation*. 2017; **101**: 2612.

54. van Dijk M, van Roon AM, Said MY, et al. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial. *Transplant international : official journal of the European Society for Organ Transplantation*. 2018; **31**: 1380.

55. Murbraech K, Massey R, Undset LH, Midtvedt K, Holdaas H, Aakhus S. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. *Clinical transplantation*. 2015; **29**: 678.

56. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *The New England journal of medicine*. 2012; **367**: 329.

57.   Pratschke J, Dragun D, Hauser IA, et al. Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation. *Transplantation reviews (Orlando, Fla)*. 2016; **30**: 77.

58.   Papaz T, Allen U, Blydt-Hansen T, et al. Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE Study): The Collaboration and Design of a National Transplant Precision Medicine Program. *Transplantation direct*. 2018; **4**: e410.

59.   Anglicheau D, Naesens M, Essig M, Gwinner W, Marquet P. Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches. *Transplantation*. 2016; **100**: 2024.

60.   Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *The New England journal of medicine*. 2007; **357**: 2562.

Legends to figures

Figure 1: Overview of study medication

Target levels CsA during the first month after transplantation: 200 ng/mL (range 150-250 ng/mL) for C-0h and 1000 ng/mL (range 900-1100 ng/mL) for C-2h; during the second and third month 150ng/mL (range 100-200 ng/mL) for C-Oh and 900 ng/mL (range 800-1000 ng/mL) for C-2h.

Group 1 (CsA/MPA arm): Target levels for CsA after 90 days: 100-150 ng/mL for C-Oh and 750 ng/mL for C-2h. Discontinuation of steroids on day 90.

Group 2 (EVL/MPA/steroids arm): everolimus started at three months after transplantation with simultaneous decrease of CsA-dose by 50% and discontinuation when EVL trough levels were within the therapeutic range.

CsA = cyclosporine; MPA = enteric coated mycophenolic acid; MP = methylprednisolone.

Figure 2 : Study Flow Chart

All primary and secondary outcomes were evaluated/analyzed on the modified intention-to-treat population (mITT) defined as all patients who received at least one day of the allocated regimen

CsA = cyclosporine; MPA = mycophenolic acid

[1] deteriorating graft function : N=2; prolonged delayed graft function : N=2; wound healing problems : N=3; administrative problems/unknown reasons : N=5

Figure 3: Death‑censored graft survival and overall graft survival (mITT analysis)

CsA = cyclosporine

EVL = everolimus

Table 1. Baseline donor and recipient characteristics (mITT analysis)			
	CsA + Mycophenolate	Everolimus + Mycophenolate + Steroids	P
Number of recipients	70	54	
Recipient age (years)	55 ± 12	51 ± 11	0.094
Gender (M/F)	50/20	37/17	0.73
Ethnicity (Caucasian) (%)	94	94	1.0
Dialysis vintage (months)	30 ± 18	22 ± 17	0.0115
Panel Reactive Antibodies (%)	0.8 ± 3.5	0.5 ± 2.6	0.65
Number of HLA mismatches	2.7 ± 1.3	2.5 ± 1.2	0.56
Cold ischemia time (hours)	13 ± 5	14 ± 6	0,68
2nd warm ischemia time (min)	28 ± 10	30 ± 7	0.33
Donor age (years)	45 ± 13	46 ± 12	0.56
Type of donor (%)			0.0337
Brain dead	61	40	
Living	6	6	

Non heart beating	3	8	

Table 2. Therapeutic drug monitoring data of cyclosporine (CsA) and everolimus (EVL)[1,3] (mITT analysis)

		W1	M1	M3	M6	Y1	Y2	Y3	Y4	Y5
CsA/MPA n = 70	C0 (ng/ml)	234	247	209	187	157	164	133	145	163
	C2 (ng/ml)	1085	1108	802	776	692	696	696	660	684
	MPA[2] (mg/day)	1466	1466	1327	1270	1299	1253	1194	1199	1150
EVL/MPA/Steroids n = 54	C0 (ng/ml)	227	225	193						
	C2 (ng/ml)	995	1088	945						
	MPA[2] (mg/day)	1454	1480	1387	1219	1117	1038	1008	977	941
	EVL (ng/ml)				7.8	8.7	8.0	6.7	6.9	7.7

[1] Results are expressed as arithmetic mean of available values

[2] Daily dose of mycophenolic acid (MPA)

[3] Each time point included values from at least 75% of patients

Table 3. [51]CrEDTA and MDRD clearance[1]

[51]CrEDTA[2]	mITT			ITT			OT		
	CsA /MPA n=70	EVL/MPA/steroids n=54	*p*	CsA /MPA n=76	EVL/MPA/steroids n=75	*p*	CsA /MPA	EVL/MPA/steroids	*p*
M 3	55.7 ± 18 (62)	55.6 ± 14 (51)	0.98	54.6± 18 (65)	53.5 ± 14 (61)	0.69	54.6± 18 (65)	53.5 ± 14 (61)	0.69
Y 1	51.8 ± 18 (53)	57.6 ± 18 (43)	0.11	51.5 ± 18 (55)	55.8± 17 (51)	0.21	52.4 ± 20 (33)	61.6 ± 17 (32)	0.050
Y 5	46.3 ± 17 (40)	54.3 ± 21 (30)	0.09	46.5 ± 17 (41)	52.5 ± 21 (37)	0.17	46.2 ± 16 (20)	59.1 ± 19 (13)	0.042

MDRD[2]	mITT			ITT			OT		
	CsA /MPA	EVL/MPA/steroids	*p*	CsA /MPA	EVL/MPA/steroids	*p*	CsA /MPA	EVL/MPA/steroids	*P*
M 3	51.0 ± 13 (68)	51.0 ± 12 (53)	0.99	50.0 ± 14 (71)	49.0 ± 12 (70)	0.66	50.0 ± 14 (71)	49.0 ± 12 (70)	0.66
Y 1	49.7 ± 11 (65)	54.1 ± 15 (49)	0.08	48.5 ± 12 (68)	51.7 ± 15 (63)	0.18	51.6 ± 10 (38)	56.5 ± 12 (35)	0.07
Y 5	49.8 ± 17 (51)	54.2 ± 21 (42)	0.29	49.4 ± 17 (54)	52.6 ± 21 (52)	0.39	51.3 ± 18 (23)	60.6 ± 22 (21)	0.13

[1] mean ± standard deviation

[2] results are expressed as ml/min/1.73 m[2]

[3] at three months after transplantation, the OT population does not differ from the ITT population. At this moment patients in both treatment arms still received standard triple therapy with CsA/MPA/steroids.

M3: 3 months after transplantation, Y1: 1 year after transplantation, Y5: 5 years after transplantation, MITT: modified intention-to-treat, ITT: intention-to-treat, OT: on-treatment

Table 4. Biopsy-proven acute rejection (BPAR) episodes after 3 months and treatments administered for acute rejection[1]			
		CsA/MPA n=70	EVL/ MPA/Steroids n=54
BPAR ≥ 3months	Total	11	10
	Classification	4 Borderline 3 Banff IA 1Banff IIA 1 Banff IIB 1ABMR GrI 1 ABMR Gr II	1 Borderline 4 Banff IA 1 Banff IIA 3 Banff IIB 1 ABMR Gr II + Borderline changes
	Treatment[2]	7 MP 1 MP + ATG 2MP + PEX + IvIg 1 MP + IV Ig	5 MP 2MP + ATG + PEX + IvIg 3 MP + PEX + IvIg

[1] mITT analysis

[2] MP: methylprednisolone, PEX: plasma-exchange therapy, ATG: anti-thymocyte globulin, IvIg: intravenous immunoglobulins

During the first 3 months with all patients receiving CsA/MPA/steroids, 8 BPAR occurred in 151 patients

Table 5. Adverse events

Infections : incidence and type[1]

	CsA/MPA n=70(%)[2]	EVL/MPA/steroids n=54 (%)[2]	*p*
Total	226	212	0.04
Urinary Tract	90 (39%)	57 (24%)	0.0005
Pulmonary	31 (14%)	53 (22%)	0.025
Gastrointestinal	14 (6%)	25 (10%)	0. 11
Ear, nose and throat	34 (15%)	27 (11%)	0.19
Dermatological	19 (8%)	29 (12%)	0.15
Blood/lymph	6 (3%)	5 (2%)	0.49
CMV [4]	18 (8%)	18 (7%)	0.68
BKV[5]	10 (4%)	9 (4%)	1
Musculoskeletal	3 (1%)	5 (2%)	0.38
Wound	1 (0.4%)	1 (0.4%)	1
Other	2 (0.8%)	3 (1.2%)	0.66
SAE due to infection	49 (21.7%)	68 (28.2%)	*P*=0.0015

Incidence of malignancies and type of malignancy (number of malignancies)[1]

|	CsA/MPA n=70(%)[3]	EVL/MPA/steroids n=54 (%)[3]	*p*
Overall	14	19	0.06
Solid tumor	8	10	0.26
Skin	6	9	0.98
Patients developing at least one malignancy	11 (15.7)	15 (27.7)	0.1

[1] mITT analysis

[2] %: percentage of total number of infections

[3] proportion of patients

[4] CMV replication or disease not specified in AE reports

[5] BKV replication or nephropathy not specified in AE reports

tri_13798_f1.gif

CONSORT Flow Diagram: CISTCERT trial

Transplanted in recruiting hospitals during study period (N=622)

↓

Assessed for eligibility (N=155)

Excluded (N=4)
- Not meeting inclusion criteria (N=2)
- Other reasons (N=2)

↓

Randomized within 24 hours before transplantation (N=151)
All patients treated with basiliximab + cyclosporine + mycophenolic acid + methylprednisolone for 3 months after transplantation

↓

- **Group 1: CsA + MPA (stop steroids; N=76)**
- **Never received allocated treatment (N=6)**
  - Acute rejection <3 months (N=1)
  - Adverse effect of CsA (N=2)
  - Graft loss (N =2)
  - Withdrawal of consent (N=1)
- **Received allocated treatment >=1 day (N=70)**

- **Group 2: everolimus + MPA + steroids (stop CsA; N=75)**
- **Never received allocated treatment (N=21)**
  - Acute rejection <3 months (N= 2)
  - Adverse effects of CsA/MPA (N= 2)
  - Graft loss(N =1)
  - Patient death (N=1)
  - Withdrawal of consent (N=3)
  - Other/unknown reason (N = 12) [1]
- **Received allocated treatment >=1 day (N=54)**

↓

- **Censoring events between 3 and 12 months (N=0)**
  - Patient death (N=0)
  - Graft loss (N=0)
  - Withdrawal of consent (N=0)
  - Lost to follow up (N=0)
- **Stop of allocated treatment between 3 M and 12 M (N= 29)**
- **Evaluation of outcomes at 12 months (N=70)**
  - On allocated treatment (N= 41)
  - On other regimen (N= 29)

- **Censoring events between 3 and 12 months (N=1)**
  - Patient death (N=0)
  - Graft loss (N=0)
  - Withdrawal of consent (N=0)
  - Lost to follow up (N=1)
- **Stop of allocated treatment between 3 M and 12 M (N= 16)**
- **Evaluation of outcomes at 12 months (N=53)**
  - On allocated treatment (N=37)
  - On other regimen (N=16)

↓

- **Censoring events between 1 and 5 years (N=17)**
  - Patient death (N=7)
  - Graft loss (N=0)
  - Withdrawal of consent (N=4)
  - Lost to follow up (N=6)
- **Stop of allocated treatment between 1 and 5 years (N= 20)**
- **Evaluation of outcomes at 5 years (N= 53)**
  - On allocated treatment (N= 25)
  - On other regimen (N= 28)

- **Censoring events between 1 and 5 years (N=12)**
  - Patient death (N=7)
  - Graft loss (N=2)
  - Withdrawal of consent (N=2)
  - Lost to follow up (N=1)
- **Stop of allocated treatment between 1 and 5 years (N= 12)**
- **Evaluation of outcomes at 5 years (N= 43)**
  - On allocated treatment (N= 20)
  - On other regimen (N= 23)

Death-censored graft survival[1]

Overall graft survival [1]